Urso ursodeoxycholic acid: Phase II; Marketed to treat primary biliary cirrhosis

Interim analysis of 258 patients from AXP's 716-patient North American Phase II trial

Read the full 137 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE